PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number,

Substitute for form 1449A/PTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Co	mplete if Known
Application Number	10/040,547
Filing Date	January 4, 2002
First Named Inventor	BLOOD, Christine H.
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	70025-04-CTP

,							PECEIVED
			<del></del>		U.S. PATENT DOC	UMENTS	RECEIVED
Exam Initial		Cite No. <sup>1</sup>	U.S. Paten Number	t Document Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Whare Rejevant PAstages of Rest van 2002 Figures Appear
CM	K		5,576,	290	Hadley	11-19-1996	
			5,674,8	339	Hruby, et al.	10-7-1997	TECH CENTER 1600/2900
			5,714,	576	Hruby, et al.	2-3-1998	
			6,051,	555	Hadley	4-18-2000	
			6,054,	556	Hruby, et al.	4-25-2000	
			5,908,8	325	Fasano, et al.	6-1-1999	
$\Box$			5,693,6	808	Bechgaard, et al.	12-2-1997	
Ch	YK		5,977,0	70	Piazza	11-2-1999	
	_						
	$\neg$						
	$\neg$						
	$\neg$	•••••					
	T				·		
	$\neg$						

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials	Cite No.1	Office <sup>3</sup>	Foreign Patent Doc Number <sup>4</sup>	ument Kind Code <sup>s</sup> (# known)		Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т8
		PCT	<del>US98/0329</del>	0	Trega Bioscienc	s 5-6-1999		
		PCT	US99/0411			a 9-2-1999		
		PCT	US99/0921	5 ==		11-4-199	)	
<i>—</i>		PCI	US99/132	2	Merck & Co.	12-16-199	9	

	 		· · · · · · · · · · · · · · · · · · ·
Examiner	L	l Date	97. 1
		Considered	120/12
Signature	/	Considered	/ /05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)

Approved for use through 10-31-99, OMB 0651-003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no COMPLETE IF KNOWN Substitute for form 1449B/PTO **Application Number** 10/040,547 INFORMATION DISCLOSURE Filing Date January 4, 2002 STATEMENT BY APPLIC First Named Inventor BLOOD, Christine (use as many sheets as neces 1633 Group Art Unit **Examiner Name** Sheet of Attorney Docket Number

Examiner Cite No. 1		Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²	
CMK		Bednarek M.A. et al., "Structure-function studies on the cyclic peptide MT-II, lactam derivative of α-melanotropin," <i>Peptides</i> , Vol. 20:401-09 (1999)	x-	
		Hadley M.E. et al., "Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists," <i>Pigment Cell Res</i> , Vol. 9:213-34 (1996)	٠	
		Haskell-Luevano C. et al., "Discovery of Prototype Peptidomimetic Agonists at the Human Melanocortin Receptors MC1R and MC4R," Journal of Medical Chemistry, Vol. 40:2133-39 (1997)		
		Hruby, V.J., et al., "Cyclic Lactam α-melanocyte-stimulating Hormone-(4-10)-NH <sub>2</sub> with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors," <i>Journal of Medicinal Chemistry</i> , Vol. 38, No. 18: 3454-61 (1995)		
		Schioth H.B. et al., "Discovery of novel melanocortin, receptor selective MSH analogues," British Journal of Pharmacology, Vol. 124:75-82 (1998)		
·		Schioth H.B. et al., "Selective properties of C- and N-terminals and core residues of the melanocyte- stimulating hormone on binding to the human melanocortin receptor subtypes," <i>European Journal of Pharmacology</i> , Vol. 349:359-66 (1998)		
CMK		Wessells H. et al., "Synthetic Melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study," <i>Journal of Urology</i> , Vol. 160:389-393 (1998)		
\ <del></del>	_	Metabolism of Brain Peptides, Ed. G. O'Cuinn, CRC Press, New York, 1995, pp. 1-9 and 99-101		

Examiner Signature	Date Considered	9/20/03
--------------------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[F:\MIKE\PATENT\IDS\Palatin\Sex Dysfunction 1449form-2-2.pat.doc]

Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box -> +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2 Sheet 1

Co	Complete if Known					
Application Number	10/040,547					
Filing Date	January 4, 2002	_				
First Named Inventor	BLOOD, Christine					
Group Art Unit	1653					
Examiner Name	C. Kam	_				
Attorney Docket Number	70025-04-CIP	_				

				U.S. PATENT DOC	UMENTS	
xaminer nitials'	Cite No.1		cument lind Code <sup>2</sup> If known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear
CMK		4,649,191	r Known)	Hruby	03/10/1987	T MOI BO AVAIN
MK		5,420,109	<b>7</b>	Suto, et al.	05/30/1995	
44		;				
1						
			_ _			
					_	
			_ _			
		ļ				
			-			
		<u> </u>				

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Cite	Cite		Foreign Patent Doc		Name of Patenties of	Date of Publication of	Pages, Columns, Lines, Where Relevant	T
nitials	No.1	Office	Number <sup>4</sup>	Kind Codes (# known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	76
CYK		FR	2 691 465		Fabre Medicament	11-26-1993	English abst	pri
CHK		FR	2 735 131		Societe D'Etude et	12-13-1996	Gralizh abst	ril
					de Recherche de			
					Pathologie Applique			
					Seroa Societe Civile			
CHK		PC1	WO 94/22460		Univ. Patents, Inc.	10-13-1994		1
						ļ	<u> </u>	┼
								+
		<del>  -  </del>	.,			1		1-

					يفاد المستحدين المستحدين
Examiner	1,	7.	Date	9/ 1	
LAGITITIO		-/ '	1	1/20/	
Signature			Considered	1 / 703	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>8</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box ->

PTC/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 2 Sheet

Compl te If Kn wn					
Application Number	10/040,547				
Filing Date	January 4, 2002				
First Named Inventor	BLOOD, Christin				
Group Art Unit	1653				
Examiner Name	C. Kam				
Attorney Docket Number	70025-04-CIP				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CHK		Low, et al., "Role of Chain Termini in Selective Steroidogenic Effect of ACTH MSh-4-10 on Isolated Adrenocortical Cells," PEPTIDES (Elmsford), Vol. 11, No. 1, 1990, pp. 29-32			

Examiner Signature	Chi		Date Considered	9/20/03
		والمستقد والمراب والمناف والمراب والمناف والمراب والمناف والمراب والمناف والمراب والمراب والمراب والمراب والمراب	<del></del>	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Tredemark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

lease type a plus	sign (+) inside	this	box →	T+
6)	1			

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

10/040,547

Complete if Known

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Group Art Unit

**Examiner Name** 

**Application Number** 

First Named Inventor

**Filing Date** 

January 4, 2002 BLOOD, Christine 1653 C. Kam

Attorney Docket Number Sheet of 70025-04-CIP

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2	
CMK		"Synthesis and Receptor Binding Analysis of Thirteen Oligomeric •-MSH Analogs," Brandenburger, Yves, et al., J. of Receptor & Signal Transduction Research, Vol. 19, No. 1-4, 1999, pp. 467-480.		
CMK		Chemical Abstracts, Chemical Substance Index, Part 5 of 9, Chemical Abstracts Service, Vol. 126, June 30, 1997, pg. 9239CS and 9257CS		
		RECEIVED		
-		NOV 2 9 2002		
		TECH CENTER 1600/2900		
			$\exists$	

	Examiner Signature	Cht_/		Date Considered	9/20/03
--	-----------------------	-------	--	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

